Associations between oxidized LDL to LDL ratio, HDL and vascular: Calcification in the feet of hemodialysis patients

Journal of Korean Medical Science

Volumn 24, Issue SUPPL.1, 2009, Pages

  An, Won Suk ^a   Kim, Seong Eun ^a   Kim, Ki Hyun ^a   Bae, Hae Rahn ^a   Rha, Seo Hee ^a  

^a Dong A University   (South Korea)

Author keywords

Hemodialysis; High density lipoproteins; Oxidized low density lipoprotein; Vascular calcification

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; FEMALE; FOOT; HUMAN; MALE; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RISK FACTOR;

AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FOOT; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENAL DIALYSIS; RISK FACTORS;

EID: 62449149470     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.S1.S115     Document Type: Article

References (31)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (5 Suppl 3): S112-S9.
2. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-63.
3. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-9.
4. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-42.
5. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-21.
6. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Goncalves M, Negrao AP. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1480-8.
7. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401.
8. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-40.
9. Coresh J, Longenecker JC, Miller ER, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998; 9 (12 Suppl): S24-30.
10. Fleischmann EH, Bower JD, Salahudeen AK. Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J 2001; 47: 74-81.
11. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808.
12. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003; 14: 1927-39.
13. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
14. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
15. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
16. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 1879-83.
17. Honkanen E, Kauppila L, Wikstrom B, Rensma PL, Krzesinski JM, Aasarod K, Verbeke F, Jensen PB, Mattelaer P, Volck B. CORD study group. Abdominal aortic calcification in dialysis patients: results of the CORD study. Nephrol Dial Transplant 2008; 23: 4009-15.
18. Toussaint ND, Kerr PG. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology (Carlton) 2007; 12: 500-9.
19. Porter CJ, Stavroulopoulos A, Roe SD, Pointon K, Cassidy MJ. Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes. Nephrol Dial Transplant 2007; 22: 3208-13.
20. Takenaka T, Takahashi K, Kobayashi T, Oshima E, Iwasaki S, Suzuki H. Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients. Clin Nephrol 2002; 58: 33-7.
21. Cote C, Pibarot P, Despres JP, Mohty D, Cartier A, Arsenault BJ, Couture C, Mathieu P. Association between circulating oxidized lowdensity lipoprotein and fibrocalcific remodeling of the aortic valve in aortic stenosis. Heart 2008; 94: 1175-80.
22. Krasniak A, Drozdz M, Pasowicz M, Chmiel G, Michalek M, Szu-milak D, Podolec P, Klimeczek P, Konieczynska M, Wicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC, Drueke TB, Sulowicz W. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant 2007; 22: 515-21.
23. Galland F, Duvillard L, Petit JM, Lagrost L, Vaillant G, Brun JM, Gambert P, Verges B. Effect of insulin treatment on plasma oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients. Diabetes Metab 2006; 32: 625-31.
24. Tinahones FJ, Gomez-Zumaquero JM, Garrido-Sanchez L, Garcia-Fuentes E, Rojo-Martinez G, Esteva I, Ruiz de Adana MS, Cardona F, Soriguer F. Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J Lipid Re 2005; 46: 452-7.
25. Shoji T, Kimoto E, Shinohara K, Emoto M, Ishimura E, Miki T, Tsujimoto Y, Tabata T, Nishizawa Y. The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients. Kidney Int Suppl 2003; 84: S128-30.
26. Allison MA, Pavlinac P, Wright CM. The differential associations between HDL, non-HDL and total cholesterols and atherosclerotic calcium deposits in multiple vascular beds. Atherosclerosis 2007; 194: e87-94.
27. Tamashiro M, Iseki K, Sunagawa O, Inoue T, Higa S, Afuso H, Fukiyama K. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 2001; 38: 64-9.
28. Toikka JO, Ahotupa M, Viikari JS, Niinikoski H, Taskinen M, Irjala K, Hartiala JJ, Raitakari OT. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis 1999; 147: 133-8.
29. Segarra A, Chacon P, Martinez-Eyarre C, Argelaguer X, Vila J, Ruiz P, Fort J, Bartolome J, Camps J, Moliner E, Pelegri A, Marco F, Olmos A, Piera L. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 2001; 12: 1255-63.
30. Calo LA, Naso A, Carraro G, Wratten ML, Pagnin E, Bertipaglia L, Rebeschini M, Davis PA, Piccoli A, Cascone C. Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol Dial Transplant 2007; 22: 1413-9.
31. Asmus H-G, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, Neumayer HH, Raggi P, Bommer J. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005; 20: 1653-61.s